Drug Database
AN

anti-D immunoglobulin

✓ Approved

Kedrion · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-D immunoglobulin?

anti-D immunoglobulin is a polyclonal antibodies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyKedrion
Drug ClassPolyclonal Antibodies, Cell-based Therapies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

anti-D immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMedCureus2026-08-25

Laboratory-Confirmed Hepatitis A, Hepatitis E, and Rotavirus Infections at a Tertiary Care Center in Eastern Rajasthan, India: A Prospective Observational Study.

Kaur Asmita A, Sachdev Rohit R, Upadhyay Harshita H

Background Hepatitis A virus (HAV) and hepatitis E virus (HEV) are important fecal-oral viral causes of acute hepatitis, whereas rotavirus is a major cause of acute gastroenteritis in India. Their occurrence varies by age, season, sanitation, and local exposure patterns. This prospective study assessed the laboratory positivity, temporal distribution, and clinico-epidemiological characteristics of HAV, HEV, and rotavirus infections among eligible patients tested at a tertiary care center in Eastern Rajasthan, India. Methods This prospective observational study was conducted at RVRS (Rajmata Vijaya Raje Scindia) Government Medical College, Bhilwara, Rajasthan, from January 2025 to March 2026. Eligible patients with clinically suspected acute viral hepatitis and/or acute diarrheal illness were enrolled consecutively. Demographic, socioenvironmental, clinical, and laboratory data were recorded using a structured case record form. Anti-HAV immunoglobulin M (IgM) and anti-HEV IgM antibodies were detected by enzyme-linked immunosorbent assay (ELISA), while rotavirus infection was confirmed by stool antigen testing. Results A total of 3,038 patients were tested for HEV, 2,574 for HAV, and 560 for rotavirus. Rotavirus showed the highest laboratory positivity, detected in 80/560 patients (14.3%; 95% confidence interval (CI): 11.5-17.4), followed by HAV in 350/2,574 patients (13.6%; 95% CI: 12.3-15.0) and HEV in 319/3,038 patients (10.5%; 95% CI: 9.4-11.7). Among the 749 laboratory-confirmed cases, the overall number of cases was highest during October-December 2025 (227/749, 30.3%). HEV cases peaked during July-September 2025 (113/319, 35.4%), HAV cases during January-March 2026 (123/350, 35.1%), and rotavirus cases during October-December 2025 (56/80, 70.0%). Mean age differed significantly across etiologies: HEV, 19.45 ± 10.31 years; HAV, 17.96 ± 13.49 years; and rotavirus, 4.21 ± 1.59 years (Kruskal-Wallis H = 99.64, p < 0.001). Males predominated among HAV (222/350, 63.4%) and rotavirus cases (50/80, 62.5%), whereas females predominated among HEV cases (199/319, 62.4%) (p < 0.001). Open defecation was reported more frequently among HAV (30.6%) and HEV (30.1%) cases than among rotavirus cases (12.5%) (p = 0.004). Nausea/vomiting, loss of appetite, jaundice, and dark urine were more common among HAV and HEV cases, whereas abdominal pain was most frequent among rotavirus cases (61.3%) (all p < 0.001). Conclusions HAV, HEV, and rotavirus contributed substantially to laboratory-confirmed enteric viral infections among eligible patients tested in Eastern Rajasthan. The three etiologies showed distinct seasonal, demographic, and clinical patterns. Continued prospective laboratory surveillance, timely diagnostic testing, safe water access, and improved sanitation and hygiene practices are needed to reduce the burden of these infections.

PMID 42639517
Read full article →
PubMedEnergy & fuels : an American Chemical Society journal2026-08-25

Quality Improvement of Biomass Pyrolysis Oil through Esterification.

Lindfors Christian C, Ohra-Aho Taina T, Oasmaa Anja A

Simultaneous esterification and acetalization of bio-oil with ethanol using commercial Amberlyst catalysts at temperatures between 60 and 170 °C were carried out to obtain a less acidic bio-oil with improved stability for small residual boilers. The bio-oil used in the experiments was produced from bark-free pine sawdust, and it was partially dewatered using azeotropic distillation with n-heptane before the esterification experiments. A mediocre acidity (carboxylic acid number, CAN 30-50 mg KOH/g) bio-oil was obtained by dewatering and blending the bio-oil with an alcohol. A low-acidity bio-oil (CAN 10-20 mg KOH/g) was obtained with esterification using 50 wt % of ethanol at 80 °C. At higher temperatures (110-170 °C), bio-oil sugars were hydrolyzed and converted into acids, esters, and acetals. The reactions were very dependent on the amount of ethanol. With low concentrations of ethanol (15-20 wt %), dehydration was the main pathway, which also produced water-insoluble humins in larger quantities. Higher concentrations of ethanol reduced the amount of humins and improved the stability of the oil (carbonyl content 0.82 mmol/g) at a short residence time (6 h).

PMID 42639222
Read full article →
PubMedJournal of Nepal Health Research Council2026-08-25

Association of Laboratory Parameters with Clinical Outcomes of SARS-CoV-2 Patients.

Sharma Neupane Mamata M, Hassan Hafizah Che HC, Uranw Surendra Kumar SK, Mehta Raj Kumar RK

The COVID-19 pandemic has imposed a significant burden on healthcare systems, particularly in resource-limited settings. Laboratory biomarkers may help predict disease outcomes and guide clinical decisions. However, there is limited evidence from Nepal regarding the prognostic value of these markers among hospitalized COVID-19 patients. A hospital-based observational study was conducted among 348 RT-PCR-confirmed COVID-19 patients admitted to the COVID ICUs and wards of a tertiary care hospital in Nepal between March 2022 and June 2023. Data on sociodemographic characteristics, haematological parameters, liver and inflammatory markers, urine microscopy, and SARS-CoV-2 molecular gene markers were collected prospectively. Clinical outcomes were categorized as survived or died. Descriptive statistics, chi-square tests, and binary logistic regression were used to analyse associations and identify predictors of mortality. Out of the total 348 patients included in the study, 71 patients (20.4%) died, while 277 patients (79.6%) survived. Among 348 patients, significant associations with mortality were observed for lymphopenia (p = .001), neutrophilia (p < .001), elevated ALT (p < .001), elevated AST (p = .001), and positive D-dimer (p < .001). High viral load (Ct value ?20) for E, N, and ORF1ab ab genes was also significantly associated with mortality in univariate analysis. Logistic regression identified D-dimer positivity (OR = 0.027, p = .001) and elevated ALT (OR = 0.356, p = .016) as independent predictors of mortality. Laboratory parameters, especially lymphocyte count, D-dimer, and ALT levels, are valuable prognostic indicators of clinical outcomes in hospitalized COVID-19 patients. Integrating these markers into clinical assessment may enhance early risk stratification and resource allocation.

PMID 42638237
Read full article →
PubMedThe American journal of managed care2026-08-25

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies.

Scannell Christopher C, Romley John A JA, Myerson Rebecca R, Goldman Dana D et al.

The glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide has several branded versions, including Wegovy, which was initially approved for chronic weight management. In March 2024, the FDA expanded Wegovy's indications to include reducing cardiovascular events in patients with overweight or obesity and cardiovascular disease. That same month, Medicare Part D expanded coverage for this indication. Evidence is lacking on how these policy changes have affected the utilization of Wegovy and other semaglutide products. Retrospective analysis of monthly semaglutide fills in the US before and after expanded FDA indications and Medicare coverage. IQVIA National Prescription Audit PayerTrak data were used to assess temporal trends in semaglutide utilization by brand and payer between September 2023 and September 2024. Additionally, linear segmented regression was used to identify the number of additional fills associated with the FDA and Medicare policy changes. Total semaglutide utilization increased during the study period, with Wegovy showing the largest relative increase compared with the prepolicy period (136.4%) among all semaglutide products. The greatest increase in relative utilization by payer was for Wegovy purchased through Medicare Part D (598.1%). Policy implementation was associated with an estimated 592,624 additional Wegovy fills by September 2024. Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D. These policies may serve as a template for improving access to semaglutide and other GLP-1 RAs as the clinical indications for these drugs continue to expand.

PMID 42640207
Read full article →
PubMedClinical pediatrics2026-08-25

Successful Therapy of CNS Tuberculosis With Granulomatous Inflammation in Immunodeficiency.

Cagdas Deniz D, Gocmen Rahsan R, Sonmez Gamze G, Akarsu Aysegul A et al.

Central nervous system (CNS) tuberculosis (TB) carries high mortality and neurologic sequelae, especially when unrecognized inborn errors of immunity are present. We report a young woman with refractory TB meningitis, multiple intracranial tuberculomas, hydrocephalus, and intracranial hypertension despite 10 months of standard anti-TB therapy and corticosteroids. Severe vomiting led to poor adherence and severe weight loss. As immunologic evaluation suggested atypical combined immunodeficiency (CID); monthly intravenous immunoglobulin (IVIG) was started. Neurosurgery did not give indication for shunt surgery. Given the severity and presumed impaired antimycobacterial immunity, adjuvant interferon-γ (IFN-γ; 50 µg/m² 3 times weekly) was added to therapy with steroids. Vomiting resolved, weight improved, and treatment was tolerated. Serial magnetic resonance imaging showed reduction in leptomeningeal enhancement and tuberculoma burden without surgery; no neurologic sequelae developed. Next-generation sequencing identified a homozygous NHEJ1 variant, not confirmed by Sanger, but findings supported CID. In refractory CNS-TB with suspected immunodeficiency, IFN-γ, steroids, IVIG in addition to anti-TB therapy may improve outcomes and avoid neurosurgical intervention. Early immunological evaluation and host-directed therapy should be considered.

PMID 42638394
Read full article →
PubMedFrontiers in immunology2026-08-25

Glucolipid metabolic dysfunction in ankylosing spondylitis: inflammatory mechanisms, immune-metabolic crosstalk and therapeutic implications of natural products and traditional Chinese medicine.

Dong Xiaofei X, Zhang Jingjing J, Chen Zixuan Z, Liang Yeqi Y et al.

Ankylosing spondylitis (AS) is increasingly recognized as a systemic inflammatory disease accompanied by substantial glucolipid metabolic disturbances and an elevated risk of diabetes. Beyond articular inflammation, persistent immune activation reshapes metabolic homeostasis through interconnected mechanisms involving chronic cytokine signaling, immune-cell metabolic reprogramming, gut microbiota dysbiosis and endocrine disruption. Key mediators, including TNF-α, IL-6 and IL-17, promote insulin resistance, lipid abnormalities and endothelial dysfunction, while Th17/Treg imbalance, neutrophil activation and microbial metabolite alterations further amplify metabolic injury. These pathogenic interactions establish a self-reinforcing cycle in which inflammation and metabolic dysfunction mutually exacerbate one another. Emerging evidence also indicates that anti-inflammatory therapies, nutritional strategies and metabolic modulators may provide dual benefits by controlling disease activity while improving metabolic outcomes. This review summarizes the mechanistic links between AS and glucolipid dysregulation and highlights integrated therapeutic strategies, including pharmacological interventions, nutritional approaches, and natural products/traditional Chinese medicine, for reducing diabetes risk and improving long-term prognosis in AS.

PMID 42638887
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-D immunoglobulin